A study on a protein in high-grade ovarian cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This study looks at a protein called DHODH in a type of ovarian cancer. It compares two treatment approaches to see if the protein can help predict how well the cancer responds to therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have high-grade serous ovarian cancer (a specific and aggressive type).
- There must be enough stored tumor tissue (FFPE block) available for testing.
- Your treatment plan must be known (either surgery first or chemo first).
- Your medical records must include how long you stayed cancer-free after platinum chemo and your overall survival data.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how to best detect the HER2 protein in high-grade serous ovarian cancer. The goal is to improve treatment choices for people with this type of cancer.
This study is for people with a specific type of ovarian cancer (high-grade serous) who have not yet had surgery. It looks at how the cancer may resist standard chemotherapy and aims to find ways to overcome that resistance.
This study collects tumor samples from people newly diagnosed with advanced ovarian cancer to test for HRD, a genetic feature that may help doctors predict which treatments work best. The goal is to see if HRD testing can guide future treatment decisions for patients like you.
This study looks at how women with advanced ovarian cancer respond to treatments based on whether their tumors have a specific DNA repair problem called homologous recombination deficiency (HRD). It aims to understand which treatments work best for different HRD test results.
This trial uses a special imaging technique to study high-grade serous ovarian cancer. It aims to better understand the tumor to improve treatment. If you have advanced ovarian cancer and are scheduled for surgery, you may be eligible.
This trial uses artificial intelligence to guide personalized treatment for people with a specific type of ovarian cancer (high-grade serous carcinoma). It aims to improve outcomes by analyzing your tumor tissue and medical history.
Hear when a new HGSOC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.